Want to see JYNT full AI Analyst Report?
JYNT Stock Chart & Stats
$8.43
$0.22(2.63%)
At close: 4:00 PM EDT
$8.43
$0.22(2.63%)
Day’s Range― - ―
52-Week Range$6.79 - $10.67
Previous Close$8.57
Volume61.03K
Average Volume (3M)89.85K
Market Cap
$101.69M
Enterprise Value$104.15M
Total Cash (Recent Filing)$22.16M
Total Debt (Recent Filing)$2.04M
Price to Earnings (P/E)27.1
Beta1.08
Next Earnings
Nov 05, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding14,143,154
10 Day Avg. Volume76,955
30 Day Avg. Volume89,851
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)8.77
Price to Sales (P/S)2.40
P/FCF Ratio394.27
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit2.19
Enterprise Value/Ebitda27.07
Forecast
1Y Price Target
$10.50Price Target Upside24.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.24
Revenue Forecast (FY)$60.90M
Bulls Say, Bears Say
Bulls Say
Capital-light FranchisingRefranchising should reduce the capital and operating burden of company-owned clinics while shifting the earnings mix toward recurring royalties and fees. With only three company-owned or managed clinics expected after transfers, the model could support better scalability and cash conversion over the next several quarters.
Profit And Cash-flow RecoveryThe sharp improvement in EBITDA and operating cash flow indicates that the business is converting its evolving revenue mix into stronger financial output. If maintained, improved cash generation can fund franchise support, reduce reliance on external capital, and strengthen resilience through the refranchising period.
Conservative LeverageVery low leverage gives Joint greater financial flexibility while it completes portfolio changes and invests in franchise growth. A conservative capital structure limits interest burden and refinancing exposure, allowing more internally generated cash to support operations and strategic initiatives over the medium term.
Bears Say
Weak Same-store DemandDeclining system-wide sales and negative comparable sales point to continuing pressure on patient demand and franchisee revenue productivity. Because royalties depend on clinic sales, persistent weakness could constrain near-term revenue growth, delay operating leverage, and make the expected recovery dependent on successful retention and marketing efforts.
Slower Clinic ExpansionLower opening expectations and net clinic contraction reduce the pace at which Joint can expand its royalty base. Although closures may improve portfolio quality, fewer additions limit unit-driven growth over the next several quarters and place greater importance on comparable-sales recovery and franchisee performance.
Refranchising Execution And Cash UseThe Texas transaction requires a meaningful upfront cash commitment and possible earnout while the company is still completing complex clinic transfers. This can absorb liquidity and create execution risk, particularly if lease assignments or other transition steps take longer than expected and delay the benefits of the target operating model.
Joint News
JYNT FAQ
What was Joint Corp’s price range in the past 12 months?
Joint Corp lowest stock price was $6.79 and its highest was $10.67 in the past 12 months.
What is Joint Corp’s market cap?
Joint Corp’s market cap is $101.69M.
When is Joint Corp’s upcoming earnings report date?
Joint Corp’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Joint Corp’s earnings last quarter?
Joint Corp released its earnings results on Aug 06, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of $0.047 by -$0.057.
Is Joint Corp overvalued?
According to Wall Street analysts Joint Corp’s price is currently Undervalued.
Does Joint Corp pay dividends?
Joint Corp does not currently pay dividends.
What is Joint Corp’s EPS estimate?
Joint Corp’s EPS estimate is 0.08.
How many shares outstanding does Joint Corp have?
Joint Corp has 14,143,154 shares outstanding.
What happened to Joint Corp’s price movement after its last earnings report?
Joint Corp reported an EPS of -$0.01 in its last earnings report, missing expectations of $0.047. Following the earnings report the stock price went up 1.338%.
Which hedge fund is a major shareholder of Joint Corp?
Currently, no hedge funds are holding shares in JYNT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Joint Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (24.56% Upside)
$10.50 (24.56% Upside)
Blogger Sentiment
Neutral
JYNT Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.70%
12-Months-Change
Fundamentals
Return on Equity
22.00%
Trailing 12-Months
Asset Growth
-29.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Joint Corp
The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers. Its business operations are structured into two main divisions: corporate-owned clinics and franchised facilities. The firm employs several strategic models for its expansion and day-to-day functioning, which include direct company ownership, various management agreements, licensing its brand to franchisees, and collaborating with regional development partners. As of March 1, 2022, the company maintained approximately 700 active locations throughout the United States. Founded in 2010, The Joint Corp. maintains its primary corporate headquarters in Scottsdale, Arizona.
JYNT Company Deck
JYNT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized material progress toward a capital-light franchisor model with strong improvements in core profitability and cash generation (14% revenue growth, $1.4M adjusted EBITDA gain, 152% increase in operating cash flow), near-term operational wins (best retention in 5+ years, pricing uptake, digital visibility) and disciplined capital allocation (share repurchases, RD buybacks). Offsetting risks include continuing negative comp sales (-2.8%), a 3.7% decline in system-wide sales, elevated marketing spend (+40%), reduced near-term clinic opening cadence, and timing/one-time costs associated with refranchising. Overall, the positives — particularly the sizable cash flow and margin improvements tied to refranchising and retention gains — outweigh the remaining execution and timing headwinds.View all JYNT earnings summariesJYNT Stock 12 Month Forecast
Average Price Target
$10.50
▲(24.56% Upside)
Technical Analysis
Encompass Health
―
US Physical Therapy
―
Surgery Partners
―
DocGo
―
Concentra Group Holdings Parent, Inc.
―
Ownership Overview
14.93% Insiders
13.47% Mutual Funds
43.88% Other Institutional Investors
23.84% Public Companies and
Individual Investors